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ABSTRACT: Lichen simplex chronicus (LSC) is a skin disorder characterized by chronic itching and
scratching, which can lead to thick, leathery, brownish skin, sometimes with papules and can be
associated with atopic eczema. We report the case of a 52-year-old man with a 45-year atopic condition
and presenting LSC in his dorsum. After a 3-month treatment with alitretinoin at the daily dosage of
30 mg, we have observed a moderate improvement of the hand eczema together with a substantial
clinical improvement of LSC and an almost complete resolution of pruritus. We want to report this
peculiar case to suggest the use of oral alitretinoin for LSC.
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Introduction
Lichen simplex chronicus (LSC) is a skin disorder
characterized by chronic itching and scratch-
ing, which can lead to thick, leathery, brownish
skin, sometimes with papules and can be asso-
ciated with atopic eczema. Standard thera-
peutic options include topical corticosteroids,
calcineurin inhibitors, phototherapy, retinoids,
psychopharmacological agents, systemic corti-
costeroids, and other immunomodulatory agents
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such as cyclosporin A and combinations thereof
(1).
Alitretinoin (9-cis-retinoic acid) is a novel
endogenously occurring vitamin A derivative,
which binds both retinoic acid receptors and retin-
oid X receptors. It has recently been licensed in
Italy for oral treatment of severe chronic hand
eczema (CHE) unresponsive to potent topical cor-
ticosteroids (2,3).
In the literature, only one case has been
described reporting the efficacy of alitretinoin in
extrapalmar atopic eczema (4). The authors
reported the successful oral alitretinoin treatment
of six patients suffering from diffuse atopic eczema
associated with atopic CHE lesions, whereas no
reports are available regarding its potential use in
atopic eczema.
Report
We report the case of a 52-year-old man with a
45-year history of atopy and atopic eczema.
At the first medical examination, he presented
with chronic and severe hand eczema and ery-
thematous and scratched nonconfluent papu-
les involving the dorsum (between shoulders
and the neck area) (FIG. 1A). He referred severe
pruritus.
These lesions had been present for more than a
year and had become permanent. The previous
year, the patient had carried out a cycle of 12 nar-
rowband UVB sessions, which he had to stop
because he did not tolerate the treatment.
Moreover, he resulted unresponsive to potent
topical corticosteroids both on hands and on the
dorsum.
During the first visit, the patient underwent
allergological examination and cutaneous biopsy
of a lesion on the dorsum.
The skin prick test with common allergens
revealed positive atopy markers to pollen and der-
matophagoides pteronyssinus. Patch tests were
carried out according to International Contact Der-
matitis Research Group (ICDRG) recommenda-
tions with standard and additional allergens. At
Day 4, the patient showed no reaction to the
allergens of standard SIDAPA (Italian Society of
Allergological, Occupational and Environmental
Dermatology) series.
Histopathological examination showed a
spongiotic dermatitis associated to a sparse
superficial dermal inflammatory infiltrate with
lymphocytes, rare eosinophils, and melanophages
(FIG. 1B).
These findings led to the diagnosis of LSC of the
dorsum in patient suffering from atopic dermatitis
of the hands.
FIG. 1. (A) Chronic and severe hand eczemawith erythematous and scratched nonconfluent papules on the dorsum. (B) Hyper-
orthokeratosis, parakeratosis, acanthosis, spongiosis, and a dermal lymphohistiocytic infiltrate with some eosinophils andmel-
anophages (EE ¥ 20). (C) Substantial clinical improvement of lichen simplex chronicus after 3 months of therapy with oral
alitretinoin. Resolution of papules and erythema of the dorsum.
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The patient was treated for CHE with oral alitre-
tinoin at the daily dosage of 30 mg for 12 weeks and
with emollients as a basic topical therapy.
After 3 months of treatment, a moderate
improvement of the hand eczema was observed
together with a substantial clinical improvement
of LSC (FIG. 1C). After 4 months from the end
of treatment, no recurrence of lesions has been
observed.
The clinical improvement was followed by an
almost complete resolution of pruritus. In fact,
the patients’ visual analogue scales (VAS) itch
decreased from 80 at the baseline to 10 at the end of
the treatment. The therapy was generally well tol-
erated; no cutaneous or systemic side effects were
observed.
Discussion
No studies or cases have been published so far
regarding the potential benefits of this drug in LSC.
Alitretinoin is the only retinoid that activates
both intracellular retinoid acid receptors, retinoic
acid receptors and retinoid X receptors. It is
known to have immunomodulating and anti-
inflammatory effects and a regulating action on the
keratinocyte cytokine production and leukocyte
activity. In our patient, the clinical improvement
was paralleled by a marked reduction of pruritus,
rubbing, and scratching, which had a positive
impact on quality of life and contributed to skin
lesion improvement.
Our case suggests that oral alitretinoin may con-
stitute a novel, effective, and well-tolerated treat-
ment option for exacerbated LSC refractory to
standard topical treatments.
In conclusion, our case, together with the six
cases described by Grahovac et al. (4), suggests a
potential benefit of oral alitretinoin treatment of
LSC as a manifestation of extrapalmar atopic
eczema.
However, further analysis with longer follow-ups
and randomized controlled trials are needed to
confirm our clinical observation.
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